The trademark application RYSUNVY was filed by GlaxoSmithKline Biologicals S.A., a corporation established under the laws of the Kingdom of Belgium (the "Applicant"). The application was published for oppositions on November 2, 2021, and still open for oppositions.
The application was filed in English (Spanish was selected as the second language).